Table 1

Baseline Characteristics in Patients Treated With Conventional Therapy and Those With Beraprost Sodiumlegend

VariablesConventional Group (n = 34)BPS Group (n = 24)p
Demographics
 Age (years)33 ± 1339 ± 18NS
 Gender (male/female)11/239/15NS
NYHA functional class
 III (n)3122NS
 IV (n)32NS
Hemodynamics
 Heart rate, beats/min84 ± 1278 ± 16NS
 mSAP (mm Hg)81 ± 982 ± 7NS
 mPAP (mm Hg)57 ± 1656 ± 15NS
 CO (liters/min)3.5 ± 1.63.6 ± 1.1NS
 TPR (Wood units)19 ± 817 ± 7NS
 RAP (mm Hg)6 ± 47 ± 3NS
 PCWP (mm Hg)7 ± 38 ± 3NS
Pulmonary function
 PaO2(mm Hg)73 ± 1172 ± 12NS
 PaCO2(mm Hg)31 ± 434 ± 4NS
 SvO2(%)62 ± 962 ± 8NS
 FVC (% predicted)89 ± 1588 ± 16NS
 FEV1 (% predicted)79 ± 1081 ± 10NS
Medication use at discharge
 Anticoagulant agents (%)7663NS
 Calcium antagonists (%)3812<0.05
 Nitrates (%)1812NS
 Digitalis (%)7025<0.01
 Diuretics (%)7058NS
 Home oxygen therapy (%)5958NS
  • legend BPS = beraprost sodium; CO = cardiac output; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; mPAP = mean pulmonary arterial pressure; mSAP = mean systemic arterial pressure; NS = not significant; NYHA = New York Heart Association functional class; PaCO2= arterial carbon dioxide pressure; PaO2= arterial oxygen pressure; PCWP = pulmonary capillary wedge pressure; RAP = mean right atrial pressure; SvO2= mixed venous oxygen saturation; TPR = total pulmonary resistance.